☆ 4.5 Article

Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone

NATURE REVIEWS RHEUMATOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Medicine, Research & Experimental

Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review

David L. Kendler et al.

Summary: Denosumab, a fully human monoclonal antibody, has shown to be highly effective in treating osteoporosis and reducing fracture risk in high-risk patients. Long-term studies have demonstrated gradual increases in bone mineral density and sustained low rates of fractures with minimal side effects.

ADVANCES IN THERAPY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Bone Mineral and Organic Properties in Postmenopausal Women Treated With Denosumab for Up to 10 years

Delphine Farlay et al.

Summary: In postmenopausal women with osteoporosis, denosumab therapy for 10 years significantly increased bone mineralization, with more pronounced changes within the first 5 years. The study showed that denosumab treatment for 5 years led to a transition of mineral to more mature crystals and lower microhardness, indicating a persistence of low bone remodeling state at 5 and 10 years.

JOURNAL OF BONE AND MINERAL RESEARCH (2022)

添加到收藏夹

Review Geriatrics & Gerontology

Effects of Muscles on Bone Metabolism-with a Focus on Myokines

Beom-Jun Kim

Summary: This review discusses the research on muscle-bone crosstalk, highlighting that mechanical forces are not the only mechanism by which muscle-derived signals affect bone metabolism, and emphasizing the significance of skeletal muscles as an endocrine organ that secretes bone-regulatory factors. Both mechanical and biochemical aspects should be considered to fully understand the interaction between muscles and bones.

ANNALS OF GERIATRIC MEDICINE AND RESEARCH (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses

Felicia Cosman et al.

Summary: This post hoc analysis study found that the risk of vertebral fracture (VF) and multiple vertebral fractures (MVF) after discontinuation of a specific medication (denosumab) is related to the duration of medication use. Patients who used the medication for a longer period of time have an increased risk of developing MVF after discontinuation.

JOURNAL OF BONE AND MINERAL RESEARCH (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Transcription Factor Hematopoietically Expressed Homeobox Protein (Hhex) Negatively Regulates Osteoclast Differentiation by Controlling Cyclin-Dependent Kinase Inhibitors

Hisato Watanabe et al.

Summary: We investigated the role of hematopoietically expressed homeobox protein (Hhex) in osteoclast development. Our findings suggest that Hhex acts as an inhibitor of osteoclast differentiation through epigenetic regulation and modulation of the cell cycle of osteoclast precursors. Hhex expression is reduced during RANKL-induced osteoclastogenesis, and overexpression or suppression of Hhex affects the development of osteoclasts in vitro. Conditional deletion of Hhex in osteoclast-lineage cells promotes osteoclastogenesis and reduces cancellous bone volume in mice.

JBMR PLUS (2022)

添加到收藏夹

Review Endocrinology & Metabolism

Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS

Elena Tsourdi et al.

Summary: Discontinuation of denosumab results in increased bone turnover, rapid bone loss, and risk of multiple vertebral fractures in some patients. Prior bisphosphonate therapy or subsequent antiresorptive treatment may help mitigate the biochemical rebound phenomenon after denosumab discontinuation.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study

J. Everts-Graber et al.

Summary: Patients who received zoledronate after denosumab discontinuation had fewer vertebral fractures, while all subsequent therapies were able to maintain bone mineral density to some extent. Factors such as age, BMI, treatment duration, prior therapy, and BMD gains during denosumab treatment influenced bone mineral density loss, while bone turnover markers correlated with total hip bone loss and treatment duration.

BONE (2021)

添加到收藏夹

Correction Biochemistry & Molecular Biology

Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption (vol 184, pg 1330, 2021)

Michelle M. McDonald et al.

CELL (2021)

添加到收藏夹

Article Endocrinology & Metabolism

RANKL-Induced Increase in Cathepsin K Levels Restricts Cortical Expansion in a Periostin-Dependent Fashion: A Potential New Mechanism of Bone Fragility

Nicolas Bonnet et al.

Summary: The high levels of RANKL can induce endosteal bone loss and somewhat restrict periosteal bone formation by triggering periostin degradation through cathepsin K, providing a biological mechanism for the limited increase in cortical area in postmenopausal women.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

Peter Burckhardt et al.

Summary: The risk of vertebral fractures (VFs) after treatment with denosumab (Dmab) is associated with increase in bone resorption markers and bone mineral density during and after treatment. Bisphosphonates, especially after Dmab, have a protective effect against VFs. The risk of VFs is poorly predictable before Dmab prescription, but bone markers and BMD during and after treatment have predictive value.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study

Anne Sophie Solling et al.

Summary: This study investigated the long-term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab. Results showed that ZOL could maintain lumbar spine and hip BMD during the second year, but bone turnover still increased and bone loss occurred during the first year.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

添加到收藏夹

Article Endocrinology & Metabolism

The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation

Polyzois Makras et al.

Summary: The duration of denosumab treatment significantly influences the efficacy of subsequent zoledronate infusion in maintaining bone mineral density gains. Frequent follow-up of patients treated with denosumab for more than 3 years is advisable as additional therapeutic interventions may be necessary.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Endocrinology & Metabolism

A Comparison of Bone-Targeted Exercise With and Without Antiresorptive Bone Medication to Reduce Indices of Fracture Risk in Postmenopausal Women With Low Bone Mass: The MEDEX-OP Randomized Controlled Trial

Melanie Kistler-Fischbacher et al.

Summary: The MEDEX-OP trial compared high-intensity resistance training (HiRIT) with low-intensity exercise control (BB) in postmenopausal women with low bone mass, finding that HiRIT significantly improved LS BMD and functional performance. Exercise compliance was good and both programs were well tolerated.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

添加到收藏夹

Review Orthopedics

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Lianghai Jiang et al.

Summary: Denosumab outperforms zoledronic acid in delaying first-and-subsequent skeletal-related events, with lower incidence of renal toxicity and acute phase reaction, but higher incidence of hypocalcemia and osteonecrosis of the jaw in treating advanced cancer with bone metastasis. More randomized controlled trials are needed for further evaluation.

JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis-Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage

Javier Martinez-Reina et al.

Summary: Denosumab treatment can increase bone mineral density and reduce fracture risk, but may also increase fatigue microdamage, potentially promoting fracture risk. A mechanobiological model predicts a higher risk of local failure in late treatment PMO patients in some scenarios. There is a mechanical feedback mechanism controlling excess bone mass and microdamage removal.

FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab

David W. Dempster et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial

Anne Sophie Solling et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials

Dennis M Black et al.

Lancet Diabetes & Endocrinology (2020)

添加到收藏夹

Article Cell Biology

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Keisha M. Cawley et al.

CELL REPORTS (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Sustained anti-osteoporotic action of risedronate compared to anti-RANKL antibody following discontinuation in ovariectomized mice

Toshinobu Omiya et al.

BONE REPORTS (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

Serge Ferrari et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Fracture risk following intermission of osteoporosis therapy

E. M. Dennison et al.

OSTEOPOROSIS INTERNATIONAL (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Steven R. Cummings et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis

David W. Dempster et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Coupling of bone resorption and formation by RANKL reverse signalling

Yuki Ikebuchi et al.

NATURE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment

Athanasios D. Anastasilakis et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases

Athanasios D. Anastasilakis et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Cathepsin K Controls Cortical Bone Formation by Degrading Periostin

Nicolas Bonnet et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Bone Loss After Denosumab: Only Partial Protection with Zoledronate

Ian R. Reid et al.

CALCIFIED TISSUE INTERNATIONAL (2017)

添加到收藏夹

Article Orthopedics

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

Jonathan D. Adachi et al.

BMC MUSCULOSKELETAL DISORDERS (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Influence of Fatigue Loading and Bone Turnover on Bone Strength and Pattern of Experimental Fractures of the Tibia in Mice

Nicolas Bonnet et al.

CALCIFIED TISSUE INTERNATIONAL (2016)

添加到收藏夹

Article Cell Biology

Periostin action in bone

Nicolas Bonnet et al.

MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)

添加到收藏夹

Article Endocrinology & Metabolism

Periostin expression contributes to cortical bone loss during unloading

Maude Gerbaix et al.

BONE (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

Michael S. Ominsky et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2015)

添加到收藏夹

Article Endocrinology & Metabolism

Inhibition of Cathepsin K Increases Modeling-Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys

Brenda L. Pennypacker et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Effect of ONO-5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2-Year Results From the OCEAN Study

Richard Eastell et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Novel Genetic Models of Osteoporosis by Overexpression of Human RANKL in Transgenic Mice

Vagelis Rinotas et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2014)

添加到收藏夹

Article Endocrinology & Metabolism

Postmenopausal osteoporosis treatment with antiresorptives: Effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective

Steven Boonen et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2012)

添加到收藏夹

Review Endocrinology & Metabolism

Bisphosphonates for postmenopausal osteoporosis

Richard Eastell et al.

BONE (2011)

添加到收藏夹

Review Endocrinology & Metabolism

Denosumab and bisphosphonates: Different mechanisms of action and effects

Roland Baron et al.

BONE (2011)

添加到收藏夹

Article Endocrinology & Metabolism

Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect

John A. Eisman et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2011)

添加到收藏夹

Article Endocrinology & Metabolism

Bone Remodeling in Postmenopausal Women Who Discontinued Denosumab Treatment: Off-Treatment Biopsy Study

Jacques P. Brown et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Evidence for osteocyte regulation of bone homeostasis through RANKL expression

Tomoki Nakashima et al.

NATURE MEDICINE (2011)

添加到收藏夹

Article Endocrinology & Metabolism

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts

Karen Fuller et al.

BONE (2008)

添加到收藏夹

Review Endocrinology & Metabolism

Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulation of bone remodeling in health and disease

Ann E. Kearns et al.

ENDOCRINE REVIEWS (2008)

添加到收藏夹

Article Medicine, Research & Experimental

Role of RANK ligand in mediating increased bone resorption in early postmenopausal women

G Eghbali-Fatourechi et al.

JOURNAL OF CLINICAL INVESTIGATION (2003)

添加到收藏夹

Article Endocrinology & Metabolism

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

JC Gallagher et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.